Monopar Therapeutics Annual Net Income (Loss) Attributable to Parent in USD from 2016 to 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Monopar Therapeutics quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2016 to 2024.
  • Monopar Therapeutics Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2024 was -$10.9M, a 502% decline year-over-year.
  • Monopar Therapeutics Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2024 was -$15.6M, a 85.5% decline year-over-year.
  • Monopar Therapeutics annual Net Income (Loss) Attributable to Parent for 2024 was -$15.6M, a 85.5% decline from 2023.
  • Monopar Therapeutics annual Net Income (Loss) Attributable to Parent for 2023 was -$8.4M, a 20.1% increase from 2022.
  • Monopar Therapeutics annual Net Income (Loss) Attributable to Parent for 2022 was -$10.5M, a 15.5% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$15.6M -$7.18M -85.5% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-31
2023 -$8.4M +$2.11M +20.1% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-31
2022 -$10.5M -$1.41M -15.5% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-28
2021 -$9.1M -$2.8M -44.4% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-23
2020 -$6.3M -$2.08M -49.2% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-24
2019 -$4.22M -$997K -30.9% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-25
2018 -$3.23M +$13.3M +80.5% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-27
2017 -$16.6M -$15.4M -1296% Jan 1, 2017 Dec 31, 2017 10-K 2019-02-26
2016 -$1.19M Jan 1, 2016 Dec 31, 2016 10-K 2018-03-26
* An asterisk sign (*) next to the value indicates that the value is likely invalid.